Outlook Therapeutics Inc (OTLK)
1.4800 -0.0600 (-3.90%)
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company specializes in the research and advancement of therapies aimed at addressing significant unmet medical needs in ophthalmology. Through its proprietary drug pipeline, Outlook Therapeutics is committed to enhancing the quality of life for patients affected by various retinal conditions, striving to bring new possibilities and improved outcomes to vision care.
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASDAQ: OTLK) on behalf of long-term stockholders following a class action complaint that was filed against Outlook on November 3, 2023 with a Class Period from December 29, 2022 to August 29, 2023. Our investigation concerns whether the board of directors of Outlook have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · October 11, 2024
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.
Via MarketBeat · July 11, 2024
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Via MarketBeat · June 22, 2024
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target.
Via MarketBeat · June 19, 2024
OTLK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 1, 2024
OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action – OTLK
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline.
By The Rosen Law Firm, P.A. · Via Business Wire · January 1, 2024
OTLK IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 31, 2023
OTLK DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
NEW YORK, Dec. 31, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 31, 2023
OTLK DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 30, 2023
OUTLOOK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between August 3, 2021 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire, P.C. · Via Business Wire · December 29, 2023
OTLK DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 29, 2023
OTLK DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 28, 2023
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) securities between August 3, 2021 and August 29, 2023, inclusive (the “Class Period”).
By The Law Offices of Frank R. Cruz · Via Business Wire · December 28, 2023
OUTLOOK SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 27, 2023
OUTLOOK THERAPEUTICS, INC. (NASDAQ: OTLK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Outlook Therapeutics, Inc.
NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · December 27, 2023
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between August 3, 2021 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 25, 2023
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 25, 2023
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 23, 2023
NATIONALLY RANKED ROSEN LAW FIRM Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 22, 2023
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 21, 2023
TOP RANKED ROSEN LAW FIRM Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 20, 2023
OUTLOOK ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in Outlook securities between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 19, 2023
ROSEN, A LEADING NATIONAL FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 18, 2023
OUTLOOK THERAPEUTICS, INC. (NASDAQ: OTLK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Outlook Therapeutics, Inc.
NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · December 18, 2023
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Outlook securities between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 16, 2023